Li-Nien Chien, Yan-Jun Chen, Ya-Hui Chang, Chao-Feng Lin
{"title":"Deciphering the incidence of heart failure following drug-eluting stent use in patients with high bleeding risk: a population-based cohort study.","authors":"Li-Nien Chien, Yan-Jun Chen, Ya-Hui Chang, Chao-Feng Lin","doi":"10.1097/MCA.0000000000001588","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Features of high bleeding risk (HBR) determined by the Academic Research Consortium (ARC) are linked to an enhanced risk of bleeding events among patients undergoing percutaneous coronary intervention. This population-based study investigated whether patients with ARC-HBR are at an increased risk of hospitalization for heart failure (HHF) following drug-eluting stent (DES) implantation by analyzing a large-scale national healthcare database.</p><p><strong>Methods: </strong>A total of 124 891 patients undergoing DES implantation between 1 January 2007 and 31 December 2019 were identified and divided into two groups: the ARC-HBR group and the non-ARC-HBR group. The incidence rates of HHF of patients were observed. The risk of HHF following DES implantation associated with ARC-HBR features was analyzed using a multivariable Cox proportional hazards model.</p><p><strong>Results: </strong>The incidence rates (per 1000 person-year) of HHF were 86.9 [95% confidence interval (CI): 84.3-89.6] for ARC-HBR patients and 28.8 (95% CI: 28.3-29.3) for non-ARC-HBR patients during a mean follow-up of 4.6 ± 2.9 years. After adjustment for clinical variables, ARC-HBR patients exhibited an increased risk of HHF [adjusted hazard ratio (aHR): 1.13, 95% CI: 1.08-1.19, P < 0.001], particularly among patients without a prior history of HHF (aHR: 1.31, 95% CI: 1.24-1.39, P < 0.001). These results remained consistent for patients who adhered to greater than or equal to 6 months of dual antiplatelet therapy.</p><p><strong>Conclusion: </strong>ARC-HBR patients exhibited a higher risk of HHF following DES implantation than non-ARC-HBR patients. These results highlight that the ARC-HBR feature is of clinical importance in identifying individuals at a heightened risk of developing HHF following DES implantation.</p>","PeriodicalId":10702,"journal":{"name":"Coronary artery disease","volume":" ","pages":"249-257"},"PeriodicalIF":2.0000,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Coronary artery disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MCA.0000000000001588","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Features of high bleeding risk (HBR) determined by the Academic Research Consortium (ARC) are linked to an enhanced risk of bleeding events among patients undergoing percutaneous coronary intervention. This population-based study investigated whether patients with ARC-HBR are at an increased risk of hospitalization for heart failure (HHF) following drug-eluting stent (DES) implantation by analyzing a large-scale national healthcare database.
Methods: A total of 124 891 patients undergoing DES implantation between 1 January 2007 and 31 December 2019 were identified and divided into two groups: the ARC-HBR group and the non-ARC-HBR group. The incidence rates of HHF of patients were observed. The risk of HHF following DES implantation associated with ARC-HBR features was analyzed using a multivariable Cox proportional hazards model.
Results: The incidence rates (per 1000 person-year) of HHF were 86.9 [95% confidence interval (CI): 84.3-89.6] for ARC-HBR patients and 28.8 (95% CI: 28.3-29.3) for non-ARC-HBR patients during a mean follow-up of 4.6 ± 2.9 years. After adjustment for clinical variables, ARC-HBR patients exhibited an increased risk of HHF [adjusted hazard ratio (aHR): 1.13, 95% CI: 1.08-1.19, P < 0.001], particularly among patients without a prior history of HHF (aHR: 1.31, 95% CI: 1.24-1.39, P < 0.001). These results remained consistent for patients who adhered to greater than or equal to 6 months of dual antiplatelet therapy.
Conclusion: ARC-HBR patients exhibited a higher risk of HHF following DES implantation than non-ARC-HBR patients. These results highlight that the ARC-HBR feature is of clinical importance in identifying individuals at a heightened risk of developing HHF following DES implantation.
期刊介绍：
Coronary Artery Disease welcomes reports of original research with a clinical emphasis, including observational studies, clinical trials, translational research, novel imaging, pharmacology and interventional approaches as well as advances in laboratory research that contribute to the understanding of coronary artery disease. Each issue of Coronary Artery Disease is divided into four areas of focus: Original Research articles, Review in Depth articles by leading experts in the field, Editorials and Images in Coronary Artery Disease. The Editorials will comment on selected original research published in each issue of Coronary Artery Disease, as well as highlight controversies in coronary artery disease understanding and management.
Submitted artcles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
